Privately held developer of low-cost CR systems PhorMax got good news and a new leader this month. The company announced Jan. 15 that the FDA had cleared its low-cost CR system, called Phormax CR. Just days earlier, the company welcomed Marvin Slosman as
Privately held developer of low-cost CR systems PhorMax got good news and a new leader this month. The company announced Jan. 15 that the FDA had cleared its low-cost CR system, called Phormax CR. Just days earlier, the company welcomed Marvin Slosman as its new president and CEO.
Slosman last served as executive vice president at Emerge Interactive, a business-to-business e-commerce market maker. While there, he guided Emerge from an early-stage startup to a successful IPO, developing and executing a strategic business plan that grew revenue from $3 million to $100 million. Along the way, the company made 11 acquisitions and partnerships. Prior to joining the B2B company, Slosman was cardiology division sales manager at Cordis, a Johnson & Johnson company. Earlier he served as vice president of business development and sales programs for GE Capital.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.